Back
Menu
Sarcoidosis is a multisystemic disorder of unknown etiology, characterized by granuloma formation.
Tests generally appear in the order most useful for common clinical situations
| Test name: Calcium, Serum or Plasma |
| ARUP #: 0020027 |
| Methodology: Quantitative Spectrophotometry |
| Use: Evaluate for hypercalcemia |
| Test name: Alkaline Phosphatase, Serum or Plasma |
| ARUP #: 0020005 |
| Methodology: Quantitative Enzymatic |
| Use: Evaluate hepatic involvement |
| Test name: Hepatic Function Panel |
| ARUP #: 0020416 |
| Methodology: Quantitative Enzymatic/Quantitative Spectrophotometry |
| Use: Evaluate hepatic involvement |
| Test name: Angiotensin Converting Enzyme, Serum |
| ARUP #: 0080001 |
| Methodology: Quantitative Enzymatic |
| Use: Support diagnosis of sarcoidosis or neurosarcoidosis via ACE levels in serum May be used to evaluate treatment response |
| Limitations: Antihypertensive medications such as ACE inhibitors, ACE receptor blockers, and diuretics may interfere with test results Test is a nonspecific indicator of response to treatment; not specific for diagnosis In neurosarcoidosis, serum ACE concentrations are less likely to be elevated than CSF ACE concentrations; CSF ACE levels are increased in about 55% of patients with neurosarcoidosis, 5% of those with sarcoidosis (without neurologic abnormality), and 13% of those with other neurological diseases |
| Follow-up: Further tissue biopsy and evaluation for granulomas is necessary to confirm the diagnosis |
| Test name: Angiotensin Converting Enzyme, CSF |
| ARUP #: 0098974 |
| Methodology: Quantitative Spectrophotometry |
| Use: Support diagnosis of neurosarcoidosis May be used to evaluate treatment response |
| Limitations: Antihypertensive medications such as ACE inhibitors, ACE receptor blockers, and diuretics may interfere with test results Test is a nonspecific indicator of response to treatment and is not specific for sarcoidosis |
| Test name: Lymphocyte Subset Panel 4 - T-Cell Subsets Percent and Ratio, Bronchoalveolar Lavage |
| ARUP #: 0093420 |
| Methodology: Flow Cytometry |
| Use: Diagnosis sarcoidosis |
| Test name: QuantiFERON®-TB Gold In Tube & Mycobacterium tuberculosis Antibody, IgG |
| ARUP #: 2001627 |
| Methodology: Cell Culture/Quantitative Enzyme-Linked Immunosorbent Assay |
| Use: Rule out tuberculosis as etiology of other granulomas |
| Limitations: Negative result does not completely rule out TB infection; positive result does not differentiate active from latent TB |
| Test name: CBC with Platelet Count and Automated Differential |
| ARUP #: 0040003 |
| Methodology: Automated Cell Count/Differential |
| Comments: Rule out meningitis May be helpful in differentiating bacterial from viral etiology |
| Test name: Electrolyte Panel |
| ARUP #: 0020410 |
| Methodology: Quantitative Ion-Selective Electrode/Enzymatic |
| Comments: Rule out meningitis Useful in assessing metabolic derangement as cause of altered consciousness |
| Test name: Cerebrospinal Fluid (CSF) Culture and Gram Stain |
| ARUP #: 0060106 |
| Methodology: Stain/Culture/Identification |
| Comments: Rule out meningitis |
| Test name: Glucose, Plasma or Serum |
| ARUP #: 0020024 |
| Methodology: Quantitative Enzymatic |
| Comments: Rule out meningitis Useful in assessing metabolic derangement as cause of altered consciousness |
| Test name: Cell Count, CSF |
| ARUP #: 0095018 |
| Methodology: Cell Count/Differential |
| Comments: Rule out meningitis Aids in differentiating bacterial from viral meningitis |
| Test name: Glucose, CSF |
| ARUP #: 0020515 |
| Methodology: Enzymatic |
| Comments: Rule out meningitis May be helpful in differentiating bacterial from viral etiology Usually low (<10mg/dL) in bacterial meningitis and tuberculous disease |
| Test name: Protein, Total, CSF |
| ARUP #: 0020514 |
| Methodology: Reflectance Spectrophotometry |
| Comments: Rule out meningitis May be helpful in differentiating bacterial from viral etiology |